Orchid Pharma

Which are the latest news on Orchid Pharma?

Why is Orchid Pharma Ltd falling/rising?

As of 05-Sep, Orchid Pharma Ltd's stock price is rising to 954.70, reflecting a 2.14% increase after a trend reversal. The stock has shown strong long-term performance with a year-to-date increase of 25.76% and significant institutional backing, despite a recent drop in delivery volume.

As of 05-Sep, Orchid Pharma Ltd's stock price is rising, currently at 954.70, reflecting an increase of 20.0 or 2.14%. This upward movement comes after a trend reversal, as the stock has gained after four consecutive days of decline. Additionally, the stock has outperformed its sector by 2.56% today, indicating a positive performance relative to its peers.<BR><BR>The stock's performance over the longer term has also been strong, with a year-to-date increase of 25.76% and a one-year return of 32.27%, significantly outperforming the broader market, as evidenced by the Sensex's decline of 10.21% and 5.21% over the same periods. Furthermore, Orchid Pharma has shown impressive growth over three and five years, with returns of 72.75% and 137.58%, respectively.<BR><BR>Despite a recent drop in investor participation, as indicated by a 48.04% decrease in delivery volume compared to the five-day average, the stock remains liquid enough for trading. High institutional holdings at 21.55% suggest that knowledgeable investors are backing the stock, which can provide stability and confidence in its future performance. Overall, the combination of a recent price increase, strong long-term performance, and institutional support contributes to the current rise in Orchid Pharma Ltd's stock price.

Who are in the management team of Orchid Pharma?

The management team of Orchid Pharma includes Chairman Ram Gopal Agarwal, Managing Director Manish Dhanuka, Whole-time Director Mridul Dhanuka, and Company Secretary Marina Peter, along with Independent Directors Tanu Singla, Dharam Vir, Mudit Tandon, and Manoj Goyal. They oversee the company's operations and strategic direction.

The management team of Orchid Pharma includes the following individuals:<BR><BR>1. **Ram Gopal Agarwal** - Chairman (Non-Executive)<BR>2. **Manish Dhanuka** - Managing Director<BR>3. **Mridul Dhanuka** - Whole-time Director<BR>4. **Marina Peter** - Company Secretary & Compliance Officer<BR><BR>Additionally, there are several Independent Directors on the board:<BR><BR>- **Tanu Singla**<BR>- **Dharam Vir**<BR>- **Mudit Tandon**<BR>- **Manoj Goyal**<BR><BR>This team oversees the company's operations and strategic direction. If you need more specific information about their roles or responsibilities, feel free to ask!

What does Orchid Pharma do?

Orchid Pharma Ltd is a leading Indian pharmaceutical company specializing in the Pharmaceuticals & Biotechnology sector, with a market cap of INR 5,737 Cr and reported net sales of 304 Cr and net profit of 3 Cr for June 2026. The company has a P/E ratio of 320.00 and a debt-equity ratio of 0.22.

Overview:<BR>Orchid Pharma Ltd is a leading pharmaceutical company in India, operating in the Pharmaceuticals & Biotechnology industry and categorized as a Small Cap.<BR><BR>History:<BR>Orchid Pharma was incorporated in an unspecified year and has undergone status changes over time. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 304 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 3 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 5,737 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 320.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.22 <BR>Return on Equity: 0.71% <BR>Price to Book: 4.51 <BR><BR>Contact Details:<BR>Address: Orchid Towers Nungambakkam, 313 Valluvar Kottam High Road Chennai Tamil Nadu : 600034 <BR>Tel: 91-44-28211000/28230000 <BR>Email: corporate@orchidpharma.com <BR>Website: http://www.orchidpharma.com

Who are the peers of the Orchid Pharma?

Orchid Pharma's peers include Bliss GVS Pharma, Supriya Lifesci, Innova Captab, Morepen Labs, IOL Chemicals, FDC, Guj. Themis Bio, RPG LifeScience, Gufic BioScience, and Aarti Drugs. In terms of performance, Bliss GVS Pharma leads with a 1-year return of 295.64%, while Orchid Pharma has a return of 31.22%.

Peers: The peers of Orchid Pharma are Bliss GVS Pharma, Supriya Lifesci., Innova Captab, Morepen Labs., IOL Chemicals, FDC, Guj. Themis Bio., RPG LifeScience., Gufic BioScience, and Aarti Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Supriya Lifesci., Innova Captab, and Guj. Themis Bio., while Average management risk is found at Bliss GVS Pharma, Orchid Pharma, Morepen Labs., IOL Chemicals, FDC, RPG LifeScience, Gufic BioScience, and Aarti Drugs. Growth is rated as Below Average for Bliss GVS Pharma, Supriya Lifesci., Orchid Pharma, Morepen Labs., IOL Chemicals, FDC, and RPG LifeScience, while Average growth is seen at Innova Captab, and Good growth is noted at Guj. Themis Bio. Capital Structure is rated as Excellent for Bliss GVS Pharma, Supriya Lifesci., Innova Captab, Morepen Labs., IOL Chemicals, FDC, and Guj. Themis Bio., while Below Average is noted for Orchid Pharma, and Good for Gufic BioScience and Aarti Drugs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bliss GVS Pharma at 295.64%, while the lowest is FDC at -26.41%. Orchid Pharma's 1-year return of 31.22% is higher than FDC's but lower than Bliss GVS Pharma's. Additionally, FDC is the only peer with a negative six-month return.

How big is Orchid Pharma?

As of 31st August, Orchid Pharma Ltd has a market capitalization of 5,737.00 Cr, with recent net sales of 1,073.29 Cr and a net profit of 10.73 Cr.

As of 31st August, Orchid Pharma Ltd has a market capitalization of 5,737.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Orchid Pharma reported Net Sales of 1,073.29 Cr and a Net Profit of 10.73 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 1,267.29 Cr and Total Assets of 1,687.91 Cr.

Should I buy, sell or hold Orchid Pharma Ltd?

When is the next results date for Orchid Pharma Ltd?

The next results date for Orchid Pharma Ltd is 14 August 2026.

The next results date for Orchid Pharma Ltd is scheduled for 14 August 2026.

Are Orchid Pharma Ltd latest results good or bad?

Orchid Pharma Ltd's latest Q4 FY26 results show a significant recovery in profitability, with a net profit of ₹23.78 crores and improved operating margins. However, the stock has underperformed over the past year, and high valuation metrics raise concerns about sustainability, suggesting investors should be cautious.

Orchid Pharma Ltd's latest results for Q4 FY26 indicate a significant recovery in profitability, marking a positive turnaround after two consecutive quarters of losses. The consolidated net profit reached ₹23.78 crores, which is a remarkable increase of 288.58% compared to the previous quarter. This also represents a 6.68% increase year-on-year. Additionally, net sales hit an all-time quarterly high of ₹237.61 crores, reflecting a sequential growth of 14.64%, although year-on-year growth was minimal at 0.05%.<BR><BR>The operating margin improved notably to 11.31%, up from just 0.76% in the previous quarter, indicating better operational efficiency. The profit after tax (PAT) margin also recovered to 9.59% from a negative margin of -5.86% in Q3 FY26.<BR><BR>However, despite these positive results, the company faces challenges. The stock has underperformed over the past year, declining 1.88%, and is down 29.08% over the last two years. The high valuation metrics, with a trailing P/E ratio of 140.23 times compared to the sector average of 34 times, raise concerns about sustainability and investor expectations.<BR><BR>In summary, while the latest quarter's results show strong recovery and improved profitability, the underlying issues related to valuation and past performance suggest that investors should approach with caution.

Is Orchid Pharma technically bullish or bearish?

As of December 4, 2025, the trend has shifted to mildly bullish, supported by daily moving averages and a bullish RSI on the monthly chart, though mixed signals from the MACD and Bollinger Bands indicate divergence between short-term and long-term trends.

As of 4 December 2025, the technical trend has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by the daily moving averages indicating bullish momentum. The weekly MACD is also mildly bullish, while the monthly MACD remains bearish, suggesting mixed signals across time frames. The RSI shows a bullish signal on the monthly chart, but no signal on the weekly, indicating potential strength in the longer term. Bollinger Bands are bullish on the weekly but mildly bearish on the monthly, adding to the mixed outlook. Overall, the strength of the bullish stance is moderate, with key indicators showing divergence between short-term and long-term trends.

How has been the historical performance of Orchid Pharma?

Orchid Pharma has shown significant financial improvement from March 2023 to March 2025, with net sales increasing from 665.90 Cr to 921.93 Cr, and consolidated net profit rising from 46.32 Cr to 99.66 Cr, indicating strong recovery and growth. Total assets and liabilities grew in tandem, while cash flow from operations improved markedly.

Answer:<BR>The historical performance of Orchid Pharma shows a significant improvement in financial metrics over the years, particularly from March 2023 to March 2025.<BR><BR>Breakdown:<BR>Orchid Pharma's net sales have steadily increased from 665.90 Cr in March 2023 to 921.93 Cr in March 2025, reflecting a robust growth trajectory. The total operating income followed a similar trend, rising from 665.90 Cr to 921.93 Cr during the same period. The company's operating profit (PBDIT) also improved significantly, increasing from 103.05 Cr in March 2023 to 144.65 Cr in March 2025, although the operating profit margin slightly decreased from 12.56% to 12.71%. Profit before tax rose from 55.25 Cr to 95.56 Cr, and profit after tax increased from 55.25 Cr to 95.76 Cr, indicating a strong recovery from previous losses. The consolidated net profit showed a remarkable increase from 46.32 Cr in March 2023 to 99.66 Cr in March 2025. On the balance sheet, total assets grew from 1,225.21 Cr to 1,687.91 Cr, while total liabilities increased from 1,225.21 Cr to 1,687.91 Cr, reflecting a balanced growth in both assets and liabilities. Cash flow from operating activities improved, with a net cash inflow of 17.00 Cr in March 2025 compared to a net outflow of 19.00 Cr in March 2024. Overall, Orchid Pharma's financial performance demonstrates a strong recovery and growth in key areas over the past few years.

Is Orchid Pharma overvalued or undervalued?

As of July 21, 2025, Orchid Pharma is considered overvalued with a PE ratio of 36.74 and an EV to EBITDA of 31.21, significantly higher than its peers, and has underperformed with a year-to-date return of -60.27% compared to the Sensex's gain of 5.20%.

As of 21 July 2025, Orchid Pharma's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its relative valuation. Despite this change, the company appears to be overvalued based on its current financial metrics. The PE ratio stands at 36.74, while the EV to EBITDA ratio is 31.21, both of which are significantly higher than many of its peers. Additionally, the PEG ratio of 4.17 suggests that the stock may be priced too high relative to its growth prospects.<BR><BR>In comparison to its peers, Sun Pharma has a PE of 35.52 and an EV to EBITDA of 25.11, while Cipla shows a more attractive valuation with a PE of 22.6 and an EV to EBITDA of 15.65. These comparisons highlight that Orchid Pharma's valuation is not justified when considering its earnings and growth potential. Furthermore, the company's year-to-date return of -60.27% starkly contrasts with the Sensex's gain of 5.20%, reinforcing the notion that Orchid Pharma is currently overvalued.

Who are the top shareholders of the Orchid Pharma?

The top shareholders of Orchid Pharma include Dhanuka Laboratories Limited with a 69.84% stake, mutual funds at 18.79% (led by Quant Small Cap Fund at 6.83%), Foreign Institutional Investors at 2.69%, and individual investors holding 5.11%. There are no pledged promoter holdings reported.

The top shareholders of Orchid Pharma include Dhanuka Laboratories Limited, which holds the highest promoter stake at 69.84%. Additionally, mutual funds collectively hold 18.79% of the shares, with the Quant Mutual Fund - Quant Small Cap Fund being the largest public shareholder at 6.83%. Foreign Institutional Investors (FIIs) have a stake of 2.69%, and individual investors hold 5.11% of the shares. There are no pledged promoter holdings reported.

Has Orchid Pharma declared dividend?

Orchid Pharma has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of September 13, 2012. However, the dividend yield is 0%, and total returns have shown significant volatility, with notable gains over the 5-year period despite recent declines.

Orchid Pharma Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3<BR>- Ex-date: 13 Sep 12<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -59.45%, the dividend return was 0%, resulting in a total return of -59.45%.<BR><BR>For the 1-year period, the price return was -32.95%, the dividend return was 0%, leading to a total return of -32.95%.<BR><BR>Over the 2-year period, the price return was 72.37%, with a dividend return of 0%, resulting in a total return of 72.37%.<BR><BR>In the 3-year period, the price return was 137.39%, the dividend return was 0%, culminating in a total return of 137.39%.<BR><BR>For the 4-year period, the price return was -49.4%, with a dividend return of 0%, leading to a total return of -49.4%.<BR><BR>In the 5-year period, the price return was 13462.86%, with a dividend return of 0%, resulting in a total return of 13462.86%.<BR><BR>Overall, while Orchid Pharma has declared a dividend, the dividend yield remains at 0%, indicating that the dividend has not contributed to returns in recent periods. The total returns show significant volatility, with substantial gains over longer periods, particularly in the 5-year timeframe.